Completed PHASE4 INTERVENTIONAL 4-arm NCT01448616

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Sponsor: CONRAD

Interventions Placebo Tablets Placebo Vaginal Gel TDF Vaginal TFV Gel

Updated 8 times since 2017 Last updated: Feb 14, 2023 Started: Feb 29, 2012 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Herpes Simplex Type II and is currently completed. CONRAD leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2021 — Mar 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CONRAD
Gilead Sciences
University of Washington

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States